Radius CEO: Osteoporosis Drug on Track Despite Skittish Stock - Presented by: The Aol. On Network

The recent volatility surrounding Radius Health shares should lessen as the market starts focusing on its osteoporosis drug Abaloparatide, said the company's CEO Robert Ward. Radius Health sold 6.5 million shares of stock $8 a share in a June IPO, raising $52 million.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 17.62 0.09 ▲ 0.51%
GE $ 25.62 0.48 ▲ 1.91%
AAPL $ 111.78 0.87 ▼ 0.77%
INTC $ 36.37 0.65 ▼ 1.76%
MSFT $ 47.66 0.14 ▲ 0.29%
IAG $ 2.59 0.01 ▼ 0.38%
PBR/A $ 7.34 0.17 ▲ 2.37%
VALE $ 8.14 0.53 ▲ 6.96%

As of 12/19/2014, 04:15 PM
More Most Active